Src Homology 2 (SH2) domains arose within metazoan signaling pathways and are involved in protein regulation of multiple pleiotropic cascades. In signal transducer and activator of transcription (STAT) proteins, SH2 domain interactions are critical for molecular activation and nuclear accumulation of phosphorylated STAT dimers to drive transcription. Sequencing analysis of patient samples has revealed the SH2 domain as a hotspot in the mutational landscape of STAT proteins although the functional impact for the vast majority of these mutations remains poorly characterized. Despite several well resolved structures for SH2 domain-containing proteins, structural data regarding the distinctive STAT-type SH2 domain is limited. Here, we review the unique features of STAT-type SH2 domains in the context of all currently reported STAT3 and STAT5 SH2 domain clinical mutations. The genetic volatility of specific regions in the SH2 domain can result in either activating or deactivating mutations at the same site in the domain, underscoring the delicate evolutionary balance of wild type STAT structural motifs in maintaining precise levels of cellular activity. Understanding the molecular and biophysical impact of these disease-associated mutations can uncover convergent mechanisms of action for mutations localized within the STAT SH2 domain to facilitate the development of targeted therapeutic interventions.
Keywords: SH2 domain; STAT3; STAT5; T-cell large granular lymphocytic leukemia; T-cell prolymphocytic leukemia; autosomal-dominant hyper IgE syndrome; cancer; growth hormone insensitivity syndrome; inflammatory hepatocellular adenomas; mutations.
Conflict of interest statement
The authors declare no competing interests.
Direct Targeting Options for STAT3 and STAT5 in Cancer.Cancers (Basel). 2019 Dec 3;11(12):1930. doi: 10.3390/cancers11121930. Cancers (Basel). 2019. PMID: 31817042 Free PMC article. Review.
Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis.J Exp Med. 1999 Apr 19;189(8):1229-42. doi: 10.1084/jem.189.8.1229. J Exp Med. 1999. PMID: 10209040 Free PMC article.
Somatic STAT3 mutations in large granular lymphocytic leukemia.N Engl J Med. 2012 May 17;366(20):1905-13. doi: 10.1056/NEJMoa1114885. N Engl J Med. 2012. PMID: 22591296 Free PMC article.
Novel multiplexed assay for identifying SH2 domain antagonists of STAT family proteins.PLoS One. 2013 Aug 16;8(8):e71646. doi: 10.1371/journal.pone.0071646. eCollection 2013. PLoS One. 2013. PMID: 23977103 Free PMC article.
Uncovering the pathogenesis of large granular lymphocytic leukemia-novel STAT3 and STAT5b mutations.Ann Med. 2014 May;46(3):114-22. doi: 10.3109/07853890.2014.882105. Epub 2014 Feb 11. Ann Med. 2014. PMID: 24512550 Review.
- Passerini L., Allan S.E., Battaglia M., Di Nunzio S., Alstad A.N., Levings M.K., Roncarolo M.G., Bacchetta R. STAT5-signaling cytokines regulate the expression of FOXP3 in CD4+CD25+ regulatory T cells and CD4+ CD25- effector T cells. Int. Immunol. 2008;20:421–431. doi: 10.1093/intimm/dxn002. - DOI - PubMed
- RGPIN-2014-05767/Natural Sciences and Engineering Research Council of Canada
- MOP-130424/CAPMC/ CIHR/Canada
- MOP-137036/CAPMC/ CIHR/Canada
- 950-232042/Canada Research Chair
- 703963/Canadian Cancer Society Research Institute